Global TCR-Based Antibody Market

TCR-Based Antibody Comprehensive Study by Type (NY-ESO-1, P53, WT-1, EBv), Application (Hospitals, Specialized clinics, Pharma and Biotech research laboratories., Gene therapy Centers), By Indications (Bladder cancer, Multiple myeloma) Players and Region - Global Market Outlook to 2026

TCR-Based Antibody Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global TCR-Based Antibody Market Overview:
The TCR Based Antibody is an antibody that is used when there is a need to kill the CD-19 positive cancer cells. Due to an increase in many diseases like Leukemia, Lymphoma, etc., in which normal antibodies don’t work. Thus, in such a situation the TCR-based antibody is advised by a doctor which is effectively impacting diseases. These antibodies are target explicitly and tie and kill the objective thus the transformation of the altered antibodies is expanding because of amazing outcomes. ImmTAC molecules are a novel class of T cell redirecting specific biologics that exploit TCR-based targeting of tumor cells; providing potent and highly specific access to the vast landscape of intracellular targets.

Growth Drivers
  • Rise in the adaption of the TCR-bases antibodies to create a positive impact
  • The prevalence of lymphoma through TCR based antibodies are increases across the countries

Roadblocks
  • High cost of TCR based antibody treatment for different diseases
  • Stringent rules and regulations of government regarding utilization TCR bases antibody

Opportunities
  • Development of infrastructure regarding pharmaceuticals in emerging countries
  • Development of standard rules and regulations regarding this treatment all across the globe

Challenges
  • Development of cost-efficient TCR based antibody treatment
  • Increase in demand for advanced medical and treatment procedures in emerging countries


Competitive Landscape:
This industry is fragmented by market-leading players, and those are strongly focusing on developing new methodologies by collaborating with the other company and try to get excellence in developing adoptive cell therapies. With the increase in market opportunities, the organizations are making mergers and acquisitions and availing competitive advantages.
Some of the key players profiled in the report are Immunocore (United Kingdom), Kuur Therapeutics (United States), Lion TCR (Singapore), Adaptimmune Therapeutics (United Kingdom), Celgene (United States), Kite Pharma (A Gilead Sciences Company) (United States), Takara Bio (Japan), Ziopharm Oncology (United States), GlaxoSmithKline (United Kingdom) and Merck (Germany). Additionally, following companies can also be profiled that are part of our coverage like Juno Theraprutics (United States), H3 Biomedicine (United States), Immatics (Germany), Kite Pharma (United States) and Adaptive Biotechnologies (United States). Analyst at AMA Research see United States Players to retain maximum share of Global TCR-Based Antibody market by 2026. Considering Market by By Indications, the sub-segment i.e. Bladder cancer will boost the TCR-Based Antibody market.

Latest Market Insights:
On 4 May 2021, Athenex, Inc., a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced that it has acquired Kuur Therapeutics, Inc., the leading developer of off-the-shelf CAR-NKT cell immunotherapies for the treatment of solid and hematological malignancies. Kuur’s innovative technology, combined with the TCR program, could propel us into a leadership position in cell therapy. This platform also has the potential to provide synergies with other assets in pipeline.

On 28 August 2019, Immatics Biotechnologies GmbH, a clinical-stage biopharmaceutical company active in the discovery and development of T-cell redirecting cancer immunotherapies, announced that Immatics and Celgene Corporation, a Bristol-Myers Squibb Company, have entered into a strategic collaboration and option agreement to develop novel adoptive cell therapies targeting multiple cancers. This alliance leverages Immatics’ excellence in developing adoptive cell therapies (ACT) and complements our proprietary clinical pipeline of ACT products and our strong portfolio of Bispecific products.

The food and Drug Administration (FDA) is the regulatory authority in the United States is involved in the formulation of different rules and regulations with respect to the utilization of TCR-based antibody treatment. Also, FDA is the authority that provides guidelines regarding research and development in TCR-based antibody treatment.

What Can be Explored with the TCR-Based Antibody Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global TCR-Based Antibody Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in TCR-Based Antibody
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global TCR-Based Antibody market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in TCR-Based Antibody market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Pharmaceuticals Companies, Cancer Hospitals, Government Regulatory Bodies, Private Research Institutions, Industrial Associations and Government Research Institutions.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Type
  • NY-ESO-1
  • p53
  • WT-1
  • EBv
By Application
  • Hospitals
  • Specialized clinics
  • Pharma and Biotech research laboratories.
  • Gene therapy Centers
By By Indications
  • Bladder cancer
  • Multiple myeloma

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rise in the adaption of the TCR-bases antibodies to create a positive impact
      • 3.2.2. The prevalence of lymphoma through TCR based antibodies are increases across the countries
    • 3.3. Market Challenges
      • 3.3.1. Development of cost-efficient TCR based antibody treatment
      • 3.3.2. Increase in demand for advanced medical and treatment procedures in emerging countries
    • 3.4. Market Trends
      • 3.4.1. Continuous development and finding of more T-Cell therapies
      • 3.4.2. Increase in Research for expanding product offering in relation to pharm and biotechnology
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global TCR-Based Antibody, by Type, Application, By Indications and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global TCR-Based Antibody (Value)
      • 5.2.1. Global TCR-Based Antibody by: Type (Value)
        • 5.2.1.1. NY-ESO-1
        • 5.2.1.2. P53
        • 5.2.1.3. WT-1
        • 5.2.1.4. EBv
      • 5.2.2. Global TCR-Based Antibody by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Specialized clinics
        • 5.2.2.3. Pharma and Biotech research laboratories.
        • 5.2.2.4. Gene therapy Centers
      • 5.2.3. Global TCR-Based Antibody by: By Indications (Value)
        • 5.2.3.1. Bladder cancer
        • 5.2.3.2. Multiple myeloma
      • 5.2.4. Global TCR-Based Antibody Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global TCR-Based Antibody (Price)
      • 5.3.1. Global TCR-Based Antibody by: Type (Price)
  • 6. TCR-Based Antibody: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Immunocore (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Kuur Therapeutics (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Lion TCR (Singapore)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Adaptimmune Therapeutics (United Kingdom)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Celgene (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Kite Pharma (A Gilead Sciences Company) (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Takara Bio (Japan)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Ziopharm Oncology (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. GlaxoSmithKline (United Kingdom)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Merck (Germany)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global TCR-Based Antibody Sale, by Type, Application, By Indications and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global TCR-Based Antibody (Value)
      • 7.2.1. Global TCR-Based Antibody by: Type (Value)
        • 7.2.1.1. NY-ESO-1
        • 7.2.1.2. P53
        • 7.2.1.3. WT-1
        • 7.2.1.4. EBv
      • 7.2.2. Global TCR-Based Antibody by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Specialized clinics
        • 7.2.2.3. Pharma and Biotech research laboratories.
        • 7.2.2.4. Gene therapy Centers
      • 7.2.3. Global TCR-Based Antibody by: By Indications (Value)
        • 7.2.3.1. Bladder cancer
        • 7.2.3.2. Multiple myeloma
      • 7.2.4. Global TCR-Based Antibody Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global TCR-Based Antibody (Price)
      • 7.3.1. Global TCR-Based Antibody by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. TCR-Based Antibody: by Type(USD Million)
  • Table 2. TCR-Based Antibody NY-ESO-1 , by Region USD Million (2015-2020)
  • Table 3. TCR-Based Antibody P53 , by Region USD Million (2015-2020)
  • Table 4. TCR-Based Antibody WT-1 , by Region USD Million (2015-2020)
  • Table 5. TCR-Based Antibody EBv , by Region USD Million (2015-2020)
  • Table 6. TCR-Based Antibody: by Application(USD Million)
  • Table 7. TCR-Based Antibody Hospitals , by Region USD Million (2015-2020)
  • Table 8. TCR-Based Antibody Specialized clinics , by Region USD Million (2015-2020)
  • Table 9. TCR-Based Antibody Pharma and Biotech research laboratories. , by Region USD Million (2015-2020)
  • Table 10. TCR-Based Antibody Gene therapy Centers , by Region USD Million (2015-2020)
  • Table 11. TCR-Based Antibody: by By Indications(USD Million)
  • Table 12. TCR-Based Antibody Bladder cancer , by Region USD Million (2015-2020)
  • Table 13. TCR-Based Antibody Multiple myeloma , by Region USD Million (2015-2020)
  • Table 14. South America TCR-Based Antibody, by Country USD Million (2015-2020)
  • Table 15. South America TCR-Based Antibody, by Type USD Million (2015-2020)
  • Table 16. South America TCR-Based Antibody, by Application USD Million (2015-2020)
  • Table 17. South America TCR-Based Antibody, by By Indications USD Million (2015-2020)
  • Table 18. Brazil TCR-Based Antibody, by Type USD Million (2015-2020)
  • Table 19. Brazil TCR-Based Antibody, by Application USD Million (2015-2020)
  • Table 20. Brazil TCR-Based Antibody, by By Indications USD Million (2015-2020)
  • Table 21. Argentina TCR-Based Antibody, by Type USD Million (2015-2020)
  • Table 22. Argentina TCR-Based Antibody, by Application USD Million (2015-2020)
  • Table 23. Argentina TCR-Based Antibody, by By Indications USD Million (2015-2020)
  • Table 24. Rest of South America TCR-Based Antibody, by Type USD Million (2015-2020)
  • Table 25. Rest of South America TCR-Based Antibody, by Application USD Million (2015-2020)
  • Table 26. Rest of South America TCR-Based Antibody, by By Indications USD Million (2015-2020)
  • Table 27. Asia Pacific TCR-Based Antibody, by Country USD Million (2015-2020)
  • Table 28. Asia Pacific TCR-Based Antibody, by Type USD Million (2015-2020)
  • Table 29. Asia Pacific TCR-Based Antibody, by Application USD Million (2015-2020)
  • Table 30. Asia Pacific TCR-Based Antibody, by By Indications USD Million (2015-2020)
  • Table 31. China TCR-Based Antibody, by Type USD Million (2015-2020)
  • Table 32. China TCR-Based Antibody, by Application USD Million (2015-2020)
  • Table 33. China TCR-Based Antibody, by By Indications USD Million (2015-2020)
  • Table 34. Japan TCR-Based Antibody, by Type USD Million (2015-2020)
  • Table 35. Japan TCR-Based Antibody, by Application USD Million (2015-2020)
  • Table 36. Japan TCR-Based Antibody, by By Indications USD Million (2015-2020)
  • Table 37. India TCR-Based Antibody, by Type USD Million (2015-2020)
  • Table 38. India TCR-Based Antibody, by Application USD Million (2015-2020)
  • Table 39. India TCR-Based Antibody, by By Indications USD Million (2015-2020)
  • Table 40. South Korea TCR-Based Antibody, by Type USD Million (2015-2020)
  • Table 41. South Korea TCR-Based Antibody, by Application USD Million (2015-2020)
  • Table 42. South Korea TCR-Based Antibody, by By Indications USD Million (2015-2020)
  • Table 43. Taiwan TCR-Based Antibody, by Type USD Million (2015-2020)
  • Table 44. Taiwan TCR-Based Antibody, by Application USD Million (2015-2020)
  • Table 45. Taiwan TCR-Based Antibody, by By Indications USD Million (2015-2020)
  • Table 46. Australia TCR-Based Antibody, by Type USD Million (2015-2020)
  • Table 47. Australia TCR-Based Antibody, by Application USD Million (2015-2020)
  • Table 48. Australia TCR-Based Antibody, by By Indications USD Million (2015-2020)
  • Table 49. Rest of Asia-Pacific TCR-Based Antibody, by Type USD Million (2015-2020)
  • Table 50. Rest of Asia-Pacific TCR-Based Antibody, by Application USD Million (2015-2020)
  • Table 51. Rest of Asia-Pacific TCR-Based Antibody, by By Indications USD Million (2015-2020)
  • Table 52. Europe TCR-Based Antibody, by Country USD Million (2015-2020)
  • Table 53. Europe TCR-Based Antibody, by Type USD Million (2015-2020)
  • Table 54. Europe TCR-Based Antibody, by Application USD Million (2015-2020)
  • Table 55. Europe TCR-Based Antibody, by By Indications USD Million (2015-2020)
  • Table 56. Germany TCR-Based Antibody, by Type USD Million (2015-2020)
  • Table 57. Germany TCR-Based Antibody, by Application USD Million (2015-2020)
  • Table 58. Germany TCR-Based Antibody, by By Indications USD Million (2015-2020)
  • Table 59. France TCR-Based Antibody, by Type USD Million (2015-2020)
  • Table 60. France TCR-Based Antibody, by Application USD Million (2015-2020)
  • Table 61. France TCR-Based Antibody, by By Indications USD Million (2015-2020)
  • Table 62. Italy TCR-Based Antibody, by Type USD Million (2015-2020)
  • Table 63. Italy TCR-Based Antibody, by Application USD Million (2015-2020)
  • Table 64. Italy TCR-Based Antibody, by By Indications USD Million (2015-2020)
  • Table 65. United Kingdom TCR-Based Antibody, by Type USD Million (2015-2020)
  • Table 66. United Kingdom TCR-Based Antibody, by Application USD Million (2015-2020)
  • Table 67. United Kingdom TCR-Based Antibody, by By Indications USD Million (2015-2020)
  • Table 68. Netherlands TCR-Based Antibody, by Type USD Million (2015-2020)
  • Table 69. Netherlands TCR-Based Antibody, by Application USD Million (2015-2020)
  • Table 70. Netherlands TCR-Based Antibody, by By Indications USD Million (2015-2020)
  • Table 71. Rest of Europe TCR-Based Antibody, by Type USD Million (2015-2020)
  • Table 72. Rest of Europe TCR-Based Antibody, by Application USD Million (2015-2020)
  • Table 73. Rest of Europe TCR-Based Antibody, by By Indications USD Million (2015-2020)
  • Table 74. MEA TCR-Based Antibody, by Country USD Million (2015-2020)
  • Table 75. MEA TCR-Based Antibody, by Type USD Million (2015-2020)
  • Table 76. MEA TCR-Based Antibody, by Application USD Million (2015-2020)
  • Table 77. MEA TCR-Based Antibody, by By Indications USD Million (2015-2020)
  • Table 78. Middle East TCR-Based Antibody, by Type USD Million (2015-2020)
  • Table 79. Middle East TCR-Based Antibody, by Application USD Million (2015-2020)
  • Table 80. Middle East TCR-Based Antibody, by By Indications USD Million (2015-2020)
  • Table 81. Africa TCR-Based Antibody, by Type USD Million (2015-2020)
  • Table 82. Africa TCR-Based Antibody, by Application USD Million (2015-2020)
  • Table 83. Africa TCR-Based Antibody, by By Indications USD Million (2015-2020)
  • Table 84. North America TCR-Based Antibody, by Country USD Million (2015-2020)
  • Table 85. North America TCR-Based Antibody, by Type USD Million (2015-2020)
  • Table 86. North America TCR-Based Antibody, by Application USD Million (2015-2020)
  • Table 87. North America TCR-Based Antibody, by By Indications USD Million (2015-2020)
  • Table 88. United States TCR-Based Antibody, by Type USD Million (2015-2020)
  • Table 89. United States TCR-Based Antibody, by Application USD Million (2015-2020)
  • Table 90. United States TCR-Based Antibody, by By Indications USD Million (2015-2020)
  • Table 91. Canada TCR-Based Antibody, by Type USD Million (2015-2020)
  • Table 92. Canada TCR-Based Antibody, by Application USD Million (2015-2020)
  • Table 93. Canada TCR-Based Antibody, by By Indications USD Million (2015-2020)
  • Table 94. Mexico TCR-Based Antibody, by Type USD Million (2015-2020)
  • Table 95. Mexico TCR-Based Antibody, by Application USD Million (2015-2020)
  • Table 96. Mexico TCR-Based Antibody, by By Indications USD Million (2015-2020)
  • Table 97. TCR-Based Antibody: by Type(USD/Units)
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. TCR-Based Antibody: by Type(USD Million)
  • Table 109. TCR-Based Antibody NY-ESO-1 , by Region USD Million (2021-2026)
  • Table 110. TCR-Based Antibody P53 , by Region USD Million (2021-2026)
  • Table 111. TCR-Based Antibody WT-1 , by Region USD Million (2021-2026)
  • Table 112. TCR-Based Antibody EBv , by Region USD Million (2021-2026)
  • Table 113. TCR-Based Antibody: by Application(USD Million)
  • Table 114. TCR-Based Antibody Hospitals , by Region USD Million (2021-2026)
  • Table 115. TCR-Based Antibody Specialized clinics , by Region USD Million (2021-2026)
  • Table 116. TCR-Based Antibody Pharma and Biotech research laboratories. , by Region USD Million (2021-2026)
  • Table 117. TCR-Based Antibody Gene therapy Centers , by Region USD Million (2021-2026)
  • Table 118. TCR-Based Antibody: by By Indications(USD Million)
  • Table 119. TCR-Based Antibody Bladder cancer , by Region USD Million (2021-2026)
  • Table 120. TCR-Based Antibody Multiple myeloma , by Region USD Million (2021-2026)
  • Table 121. South America TCR-Based Antibody, by Country USD Million (2021-2026)
  • Table 122. South America TCR-Based Antibody, by Type USD Million (2021-2026)
  • Table 123. South America TCR-Based Antibody, by Application USD Million (2021-2026)
  • Table 124. South America TCR-Based Antibody, by By Indications USD Million (2021-2026)
  • Table 125. Brazil TCR-Based Antibody, by Type USD Million (2021-2026)
  • Table 126. Brazil TCR-Based Antibody, by Application USD Million (2021-2026)
  • Table 127. Brazil TCR-Based Antibody, by By Indications USD Million (2021-2026)
  • Table 128. Argentina TCR-Based Antibody, by Type USD Million (2021-2026)
  • Table 129. Argentina TCR-Based Antibody, by Application USD Million (2021-2026)
  • Table 130. Argentina TCR-Based Antibody, by By Indications USD Million (2021-2026)
  • Table 131. Rest of South America TCR-Based Antibody, by Type USD Million (2021-2026)
  • Table 132. Rest of South America TCR-Based Antibody, by Application USD Million (2021-2026)
  • Table 133. Rest of South America TCR-Based Antibody, by By Indications USD Million (2021-2026)
  • Table 134. Asia Pacific TCR-Based Antibody, by Country USD Million (2021-2026)
  • Table 135. Asia Pacific TCR-Based Antibody, by Type USD Million (2021-2026)
  • Table 136. Asia Pacific TCR-Based Antibody, by Application USD Million (2021-2026)
  • Table 137. Asia Pacific TCR-Based Antibody, by By Indications USD Million (2021-2026)
  • Table 138. China TCR-Based Antibody, by Type USD Million (2021-2026)
  • Table 139. China TCR-Based Antibody, by Application USD Million (2021-2026)
  • Table 140. China TCR-Based Antibody, by By Indications USD Million (2021-2026)
  • Table 141. Japan TCR-Based Antibody, by Type USD Million (2021-2026)
  • Table 142. Japan TCR-Based Antibody, by Application USD Million (2021-2026)
  • Table 143. Japan TCR-Based Antibody, by By Indications USD Million (2021-2026)
  • Table 144. India TCR-Based Antibody, by Type USD Million (2021-2026)
  • Table 145. India TCR-Based Antibody, by Application USD Million (2021-2026)
  • Table 146. India TCR-Based Antibody, by By Indications USD Million (2021-2026)
  • Table 147. South Korea TCR-Based Antibody, by Type USD Million (2021-2026)
  • Table 148. South Korea TCR-Based Antibody, by Application USD Million (2021-2026)
  • Table 149. South Korea TCR-Based Antibody, by By Indications USD Million (2021-2026)
  • Table 150. Taiwan TCR-Based Antibody, by Type USD Million (2021-2026)
  • Table 151. Taiwan TCR-Based Antibody, by Application USD Million (2021-2026)
  • Table 152. Taiwan TCR-Based Antibody, by By Indications USD Million (2021-2026)
  • Table 153. Australia TCR-Based Antibody, by Type USD Million (2021-2026)
  • Table 154. Australia TCR-Based Antibody, by Application USD Million (2021-2026)
  • Table 155. Australia TCR-Based Antibody, by By Indications USD Million (2021-2026)
  • Table 156. Rest of Asia-Pacific TCR-Based Antibody, by Type USD Million (2021-2026)
  • Table 157. Rest of Asia-Pacific TCR-Based Antibody, by Application USD Million (2021-2026)
  • Table 158. Rest of Asia-Pacific TCR-Based Antibody, by By Indications USD Million (2021-2026)
  • Table 159. Europe TCR-Based Antibody, by Country USD Million (2021-2026)
  • Table 160. Europe TCR-Based Antibody, by Type USD Million (2021-2026)
  • Table 161. Europe TCR-Based Antibody, by Application USD Million (2021-2026)
  • Table 162. Europe TCR-Based Antibody, by By Indications USD Million (2021-2026)
  • Table 163. Germany TCR-Based Antibody, by Type USD Million (2021-2026)
  • Table 164. Germany TCR-Based Antibody, by Application USD Million (2021-2026)
  • Table 165. Germany TCR-Based Antibody, by By Indications USD Million (2021-2026)
  • Table 166. France TCR-Based Antibody, by Type USD Million (2021-2026)
  • Table 167. France TCR-Based Antibody, by Application USD Million (2021-2026)
  • Table 168. France TCR-Based Antibody, by By Indications USD Million (2021-2026)
  • Table 169. Italy TCR-Based Antibody, by Type USD Million (2021-2026)
  • Table 170. Italy TCR-Based Antibody, by Application USD Million (2021-2026)
  • Table 171. Italy TCR-Based Antibody, by By Indications USD Million (2021-2026)
  • Table 172. United Kingdom TCR-Based Antibody, by Type USD Million (2021-2026)
  • Table 173. United Kingdom TCR-Based Antibody, by Application USD Million (2021-2026)
  • Table 174. United Kingdom TCR-Based Antibody, by By Indications USD Million (2021-2026)
  • Table 175. Netherlands TCR-Based Antibody, by Type USD Million (2021-2026)
  • Table 176. Netherlands TCR-Based Antibody, by Application USD Million (2021-2026)
  • Table 177. Netherlands TCR-Based Antibody, by By Indications USD Million (2021-2026)
  • Table 178. Rest of Europe TCR-Based Antibody, by Type USD Million (2021-2026)
  • Table 179. Rest of Europe TCR-Based Antibody, by Application USD Million (2021-2026)
  • Table 180. Rest of Europe TCR-Based Antibody, by By Indications USD Million (2021-2026)
  • Table 181. MEA TCR-Based Antibody, by Country USD Million (2021-2026)
  • Table 182. MEA TCR-Based Antibody, by Type USD Million (2021-2026)
  • Table 183. MEA TCR-Based Antibody, by Application USD Million (2021-2026)
  • Table 184. MEA TCR-Based Antibody, by By Indications USD Million (2021-2026)
  • Table 185. Middle East TCR-Based Antibody, by Type USD Million (2021-2026)
  • Table 186. Middle East TCR-Based Antibody, by Application USD Million (2021-2026)
  • Table 187. Middle East TCR-Based Antibody, by By Indications USD Million (2021-2026)
  • Table 188. Africa TCR-Based Antibody, by Type USD Million (2021-2026)
  • Table 189. Africa TCR-Based Antibody, by Application USD Million (2021-2026)
  • Table 190. Africa TCR-Based Antibody, by By Indications USD Million (2021-2026)
  • Table 191. North America TCR-Based Antibody, by Country USD Million (2021-2026)
  • Table 192. North America TCR-Based Antibody, by Type USD Million (2021-2026)
  • Table 193. North America TCR-Based Antibody, by Application USD Million (2021-2026)
  • Table 194. North America TCR-Based Antibody, by By Indications USD Million (2021-2026)
  • Table 195. United States TCR-Based Antibody, by Type USD Million (2021-2026)
  • Table 196. United States TCR-Based Antibody, by Application USD Million (2021-2026)
  • Table 197. United States TCR-Based Antibody, by By Indications USD Million (2021-2026)
  • Table 198. Canada TCR-Based Antibody, by Type USD Million (2021-2026)
  • Table 199. Canada TCR-Based Antibody, by Application USD Million (2021-2026)
  • Table 200. Canada TCR-Based Antibody, by By Indications USD Million (2021-2026)
  • Table 201. Mexico TCR-Based Antibody, by Type USD Million (2021-2026)
  • Table 202. Mexico TCR-Based Antibody, by Application USD Million (2021-2026)
  • Table 203. Mexico TCR-Based Antibody, by By Indications USD Million (2021-2026)
  • Table 204. TCR-Based Antibody: by Type(USD/Units)
  • Table 205. Research Programs/Design for This Report
  • Table 206. Key Data Information from Secondary Sources
  • Table 207. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global TCR-Based Antibody: by Type USD Million (2015-2020)
  • Figure 5. Global TCR-Based Antibody: by Application USD Million (2015-2020)
  • Figure 6. Global TCR-Based Antibody: by By Indications USD Million (2015-2020)
  • Figure 7. South America TCR-Based Antibody Share (%), by Country
  • Figure 8. Asia Pacific TCR-Based Antibody Share (%), by Country
  • Figure 9. Europe TCR-Based Antibody Share (%), by Country
  • Figure 10. MEA TCR-Based Antibody Share (%), by Country
  • Figure 11. North America TCR-Based Antibody Share (%), by Country
  • Figure 12. Global TCR-Based Antibody: by Type USD/Units (2015-2020)
  • Figure 13. Global TCR-Based Antibody share by Players 2020 (%)
  • Figure 14. Global TCR-Based Antibody share by Players (Top 3) 2020(%)
  • Figure 15. Global TCR-Based Antibody share by Players (Top 5) 2020(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Immunocore (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 18. Immunocore (United Kingdom) Revenue: by Geography 2020
  • Figure 19. Kuur Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 20. Kuur Therapeutics (United States) Revenue: by Geography 2020
  • Figure 21. Lion TCR (Singapore) Revenue, Net Income and Gross profit
  • Figure 22. Lion TCR (Singapore) Revenue: by Geography 2020
  • Figure 23. Adaptimmune Therapeutics (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 24. Adaptimmune Therapeutics (United Kingdom) Revenue: by Geography 2020
  • Figure 25. Celgene (United States) Revenue, Net Income and Gross profit
  • Figure 26. Celgene (United States) Revenue: by Geography 2020
  • Figure 27. Kite Pharma (A Gilead Sciences Company) (United States) Revenue, Net Income and Gross profit
  • Figure 28. Kite Pharma (A Gilead Sciences Company) (United States) Revenue: by Geography 2020
  • Figure 29. Takara Bio (Japan) Revenue, Net Income and Gross profit
  • Figure 30. Takara Bio (Japan) Revenue: by Geography 2020
  • Figure 31. Ziopharm Oncology (United States) Revenue, Net Income and Gross profit
  • Figure 32. Ziopharm Oncology (United States) Revenue: by Geography 2020
  • Figure 33. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 34. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2020
  • Figure 35. Merck (Germany) Revenue, Net Income and Gross profit
  • Figure 36. Merck (Germany) Revenue: by Geography 2020
  • Figure 37. Global TCR-Based Antibody: by Type USD Million (2021-2026)
  • Figure 38. Global TCR-Based Antibody: by Application USD Million (2021-2026)
  • Figure 39. Global TCR-Based Antibody: by By Indications USD Million (2021-2026)
  • Figure 40. South America TCR-Based Antibody Share (%), by Country
  • Figure 41. Asia Pacific TCR-Based Antibody Share (%), by Country
  • Figure 42. Europe TCR-Based Antibody Share (%), by Country
  • Figure 43. MEA TCR-Based Antibody Share (%), by Country
  • Figure 44. North America TCR-Based Antibody Share (%), by Country
  • Figure 45. Global TCR-Based Antibody: by Type USD/Units (2021-2026)
List of companies from research coverage that are profiled in the study
  • Immunocore (United Kingdom)
  • Kuur Therapeutics (United States)
  • Lion TCR (Singapore)
  • Adaptimmune Therapeutics (United Kingdom)
  • Celgene (United States)
  • Kite Pharma (A Gilead Sciences Company) (United States)
  • Takara Bio (Japan)
  • Ziopharm Oncology (United States)
  • GlaxoSmithKline (United Kingdom)
  • Merck (Germany)
Additional players considered in the study are as follows:
Juno Theraprutics (United States) , H3 Biomedicine (United States) , Immatics (Germany) , Kite Pharma (United States) , Adaptive Biotechnologies (United States)
Select User Access Type

Key Highlights of Report


Dec 2021 210 Pages 56 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global TCR-Based Antibody Market Quantitative research analysis
Global TCR-Based Antibody Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The TCR-Based Antibody market is expected to see a CAGR of % during projected year 2020 to 2026.
Top performing companies in the Global TCR-Based Antibody market are Immunocore (United Kingdom), Kuur Therapeutics (United States), Lion TCR (Singapore), Adaptimmune Therapeutics (United Kingdom), Celgene (United States), Kite Pharma (A Gilead Sciences Company) (United States), Takara Bio (Japan), Ziopharm Oncology (United States), GlaxoSmithKline (United Kingdom) and Merck (Germany), to name a few.
"Continuous development and finding of more T-Cell therapies " is seen as one of major influencing trends for TCR-Based Antibody Market during projected period 2020-2026.

Know More About Global TCR-Based Antibody Market Report?

Have a Query? Click Here

Other Related Reports

Synthetic Biology Service- Comprehensive Study by Application (Bio-synthesis, Biofuel and Renewable Energy, Biomaterials and Green Chemicals, Skin Care & Cosmetics, Bioremediation, Biosensing, Others...
$ 3750
Human Bacterial Vaccine Comprehensive Study by Administration (Oral, Intramuscular, Intradermal, Subcutaneous, Intranasal), Category (Live Attenuated, Inactivated, Sub-Unit, Toxoid Vaccine), Indicati...
$ 3650
Period Protein Comprehensive Study by Application (Pharmaceuticals, Supplements, Others), Category (PER 1, PER 2, PER 3, Others) Players and Region - Global Market Outlook to 2026
$ 3500
Microrna Reverse Transcription Comprehensive Study by Type (Kits & reagents, Instruments, Consumables), Application (Kidney disease, Cancer, Cardiovascular disease, Neurological disease, Other), Samp...
$ 3750
Vector Based RNAi Comprehensive Study by Type (MicroRNA (miRNA), Small interfering RNA (siRNA)), Application (Neurological Disorders, Oncology, Ocular Disorders, Hepatitis B and C, Autoimmune Hepatit...
$ 3450
Parry Romberg Syndrome Comprehensive Study by End Use (Hospital, Specialty Clinic, Others), Dignosis (Physical Examination, MRI Scan, Serum Test, Others), Treatment Type (Drug Treatment, Surgery, Oth...
$ 3350